Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$136.38 USD

+0.98 (0.72%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $136.46 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

2 items in cart

View Cart/Checkout

Ascendis Pharma A/S [ASND/]

Reports for Purchase

Showing records 81 - 100 ( 303 total )

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 81

02/17/2023

Pages: 8

Q4/FY22: SKYTROFA Growth Continues; All Eyes on TC-PTH/HP PDUFA in April

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 82

02/13/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 83

01/18/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 84

01/10/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 85

01/09/2023

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 86

01/09/2023

Pages: 8

Vision 3x3 Comes Into Focus; Ophthalmology Selected as New Therapeutic Area

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 87

01/03/2023

Industry Report

Pages: 26

2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 88

01/03/2023

Industry Report

Pages: 41

Biotech vs. The Recession --> We Like The Odds

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 89

12/23/2022

Industry Report

Pages: 8

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 90

12/21/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 91

12/12/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 92

12/05/2022

Pages: 7

FDA Allows Expanded Access Program for TC-PTH Ahead of April 30, 2023 PDUFA

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 93

11/23/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 94

11/15/2022

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 95

11/14/2022

Pages: 8

Key Takeaways from Ph2 ACcompliSH Data Follow-Up Call for TC-CNP/ACH

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 96

11/14/2022

Pages: 12

Positive TC-CNP & Early TC-TLR7/8 Agonist Data Highlight TransCon''s Versatility

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 97

11/14/2022

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 98

11/11/2022

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 99

11/03/2022

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 100

11/03/2022

Pages: 8

Q3: SKYTROFA Sales Take Off; Multiple Value-Driving Catalysts in Q4

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

previous
1
2
3
4
5
6
7
8
9
...
15
16
next